The Fly

Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, expanded the marketing authorization for Dupixent in the European Union, or EU, to treat eosinophilic esophagitis, or EoE, in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on REGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More